4.7 Article

Macroscopic Assessment of Mesorectal Excision in Rectal Cancer A Useful Tool for Improving Quality Control in a Multidisciplinary Team

期刊

CANCER
卷 115, 期 15, 页码 3400-3411

出版社

WILEY
DOI: 10.1002/cncr.24387

关键词

rectal cancer; total mesorectal excision; multidisciplinary treatment; audit of surgical quality

类别

向作者/读者索取更多资源

BACKGROUND: High quality of surgical technique and the use of descriptive measures to assess and report surgical proficiency have been shown to influence locoregional tumor control in patients with rectal cancer. In this study, the authors have aimed to audit the implementation of a macroscopic assessment of mesorectal excision (MAME) and to investigate factors that influenced surgical quality and disease recurrence. METHODS: All curative resections for rectal cancer were prospectively evaluated for MAME between 1998 and 2007. Mesorectal specimens were graded into 3 types: complete, nearly complete, and incomplete categories. Univariate and multivariate analyses identified independent risk factors for noncomplete mesorectum categories as well as local and overall tumor recurrence. RESULTS: Of 359 specimens, 294 (81.9%) underwent evaluation; 82.3% were complete. Abdominoperineal resection (APR) was the sole covariate associated with inadequate mesorectal excision (odds ratio [OR] = 2.7; P = .003). Independent predictors of local recurrence were circumferential resection margin (CRM) involvement (OR = 3.6; P = .027) and noncomplete mesorectum (OR = 4.4; P = .008). CRM+ (OR = 3.1; P = .004), poorly differentiated tumors (OR = 14.2; P = .010), nodal involvement (OR = 2.9; P = .010), and APR (OR = 2.9; P = .006) were independent risk factors for overall recurrence. In lower third tumors, noncomplete mesorectum occurred more frequently in APR compared with sphincter-saving procedures (31.1% vs 18.8%; P = .088). CONCLUSIONS: This study demonstrates the value of auditing MAME, Good proficiency of mesorectal excision is associated with lower tumor recurrences after curative surgery, and is a morphological tool found to be useful in clinical practice, Cancer 2009;115:3400-11. (C) 2009 American Cancer Society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.

ANNALS OF ONCOLOGY (2021)

Article Oncology

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

Valentina Gambardella, Pasquale Lombardi, Juan Antonio Carbonell-Asins, Noelia Tarazona, Juan Miguel Cejalvo, Ines Gonzalez-Barrallo, Jorge Martin-Arana, Roberto Tebar-Martinez, Alba Viala, Gema Bruixola, Cristina Hernando, Inma Blasco, Federica Papaccio, Carolina Martinez-Ciarpaglini, Clara Alfaro-Cervello, Enrique Seda-Garcia, Sebastian Blesa, Isabel Chirivella, Josefa Castillo, Jose Vicente Monton-Bueno, Susana Rosello, Marisol Huerta, Alejandro Perez-Fidalgo, Paloma Martin-Martorell, Amelia Insa-Molla, Tania Fleitas, Pilar Rentero-Garrido, Sheila Zuniga-Trejos, Andres Cervantes, Desamparados Roda

Summary: Molecular-matched therapies have significantly improved cancer treatment outcomes, as demonstrated in this study utilizing a customized Next Generation Sequencing panel. The importance of the institutional molecular tumor board in evaluating the results and optimizing therapy selection for improved disease control was highlighted.

BRITISH JOURNAL OF CANCER (2021)

Article Oncology

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Antoine Italiano, Philippe A. Cassier, Chia-Chi Lin, Tuomo Alanko, Katriina J. Peltola, Anas Gazzah, Her-Shyong Shiah, Emiliano Calvo, Andres Cervantes, Desamparados Roda, Diego Tosi, Bo Gao, Michael Millward, Lydia Warburton, Minna Tanner, Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar, Gregory Vosganian, Victor Moreno

Summary: This study presents the safety, efficacy, pharmacokinetic, and pharmacodynamic data of budigalimab in head and neck squamous cell carcinoma and non-small cell lung cancer patients. Results showed that the drug's profiles are similar to other PD-1 inhibitors, and development in combination with novel anticancer agents is ongoing. The objective response rates and median progression-free survival varied slightly between the HNSCC and NSCLC cohorts.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Oncology

Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs

Yolanda Andreu, Paula Martinez, Ana Soto-Rubio, Silvia Fernandez, Carles Bosch, Andres Cervantes

Summary: This study aimed to determine the prevalence of distress and unmet supportive care needs in post-treatment colorectal cancer (CRC) survivors. Findings showed that one in five CRC survivors had clinical distress and 86% expressed at least one unmet need. The risk factors associated with this included lower socioeconomic status, younger age, and a primary treatment that includes more than surgery.

SUPPORTIVE CARE IN CANCER (2022)

Article Oncology

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Rosello, Anders Husted Madsen, Uffe S. Love, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kare Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, Claus Lindbjerg Andersen

Summary: The study demonstrates the strong prognostic value of serial postoperative ctDNA analysis in predicting recurrence and assessing tumor growth rate. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding treatment decisions.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients

Paula Montero, Martin Perez-Leal, Jose Alejandro Perez-Fidalgo, Celia Sanz, Cristina Estornut, Ines Roger, Javier Milara, Andres Cervantes, Julio Cortijo

Summary: Skin toxicity caused by paclitaxel could be underestimated as the adverse events may appear asymptomatic. This study found that paclitaxel alters gene and protein expression related to skin markers, and impairs the physical, physiological, and biomechanical properties of the skin in gynecological cancer patients. Prophylactic measures should be taken to prevent these subclinical alterations and potential adverse reactions.

CANCERS (2022)

News Item Oncology

CIRCULATING TUMOR DNA TO DETECT MINIMAL RESIDUAL DISEASE IN STAGE III COLORECTAL CANCER: MOVING TOWARDS CLINICAL IMPLEMENTATION

C. Montagut, V. Gambardella, M. Cabeza-Segura, T. Fleitas, A. Cervantes

ESMO OPEN (2022)

Correction Oncology

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 4, pg v238, 2018)

A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. M. Llovet, T. Meyer, J. -C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold, E. Martinelli

ANNALS OF ONCOLOGY (2022)

Article Oncology

Clinical management of metastatic colorectal cancer in the era of precision medicine

Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andres Cervantes

Summary: This review summarizes the progress in the clinical management of patients with metastatic colorectal cancer (mCRC) in the era of precision medicine. Molecular stratification, based on the current treatment algorithm, has been a significant step towards implementing more effective therapeutic approaches. Integrating tumor gene alterations with tumor and microenvironment gene and protein expression profiling, host immune competence, and applying dynamic changes to precision medicine-based continuum of care, could lead to the identification of individual prognostic and predictive parameters for choosing the most appropriate therapeutic program for each patient.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Article Oncology

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Enriqueta Felip, Victor Moreno, Daniel Morgensztern, Giuseppe Curigliano, Piotr Rutkowski, Jose Manuel Trigo, Aitana Calvo, Dariusz Kowalski, Diego Cortinovis, Ruth Plummer, Michele Maio, Paolo A. Ascierto, Vladimir Vladimirov, Andres Cervantes, Enrique Zudaire, Anasuya Hazra, Huybrecht T'jollyn, Nibedita Bandyopadhyay, James G. Greger, Edward Attiyeh, Hong Xie, Emiliano Calvo

Summary: This study assessed the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab in patients with advanced/refractory solid tumors. The results showed that cetrelimab had favorable pharmacokinetic and pharmacodynamic characteristics, as well as clinical activity, in immune-sensitive advanced cancers.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Article Oncology

The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally

Tessa Suzanne van Schooten, Sarah Derks, Elena Jimenez-Marti, Fatima Carneiro, Ceu Figueiredo, Erika Ruiz, Maria Alsina, Cristina Molero, Marcelo Garrido, Arnoldo Riquelme, Carmelo Caballero, Eva Lezcano, Juan Manuel O'Connor, Federico Esteso, Judith Farres, Jose Manuel Mas, Florian Lordick, Jeannette Vogt, Antonella Cardone, Charis Girvalaki, Andres Cervantes, Tania Fleitas

Summary: The LEGACy study is a multi-institutional research project aimed at filling the knowledge gap on gastric cancer in European and Latin American countries. It will generate novel knowledge on tumor biology characteristics by integrating epidemiological, multi-omics, and clinical data, and develop and validate cost-effective clinical decision-making methods.

BMC CANCER (2022)

Article Health Care Sciences & Services

Will Organoids Fill the Gap towards Functional Precision Medicine?

Federica Papaccio, Manuel Cabeza-Segura, Blanca Garcia-Mico, Noelia Tarazona, Desamparados Roda, Josefa Castillo, Andres Cervantes

Summary: Precision medicine approaches for solid tumors, mainly based on genomics, have shown limited success. Factors such as gene expression, genomic alterations, and the tumor microenvironment can all influence the response, making a genomics-only approach insufficient. However, the implementation of patient-derived organoids shows promise in predicting patient response to drug treatment.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Gastroenterology & Hepatology

The percentage of mesorectal infiltration as a prognostic factor after curative surgery for pT3 rectal cancer

Jorge Sancho-Muriel, Francisco Giner, Hanna Cholewa, Alvaro Garcia-Granero, Susana Rosello, Blas Flor-Lorente, Andres Cervantes, Eduardo Garcia-Granero, Matteo Frasson

Summary: The aim of this study was to evaluate the prognostic value of a novel variable, the percentage of mesorectal infiltration (PMI), in pT3 rectal cancer. The results showed that PMI was significantly associated with oncological outcomes such as local recurrence, overall recurrence, and overall survival. A PMI >60% can be used as a cut-off value for subclassifying pT3 rectal tumors and may impact decision-making in adjuvant treatment and follow-up schedule.

COLORECTAL DISEASE (2023)

News Item Oncology

LATE-STAGE METASTATIC MELANOMA EMERGES THROUGH A DIVERSITY OF EVOLUTIONARY PATHWAYS

V. Gambardella, F. Gimeno-Valiente, S. Rosello, A. Cervantes

ESMO OPEN (2023)

Article Oncology

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines

Marta Albanell-Fernandez, Sara S. Oltra, Marta Orts-Arroyo, Maider Ibarrola-Villava, Fany Carrasco, Elena Jimenez-Marti, Andres Cervantes, Isabel Castro, Jose Martinez-Lillo, Gloria Ribas

Summary: To overcome limitations of platinum-based chemotherapy, new active metallodrugs based on other transition metals are being researched. Runat-BI, a ruthenium-based compound, showed selectivity for tumoral cells and reduced tumor growth and migration in three cancer cell lines. Its mechanism of action is related to DNA synthesis and it also increases expression of proapoptotic genes. Runat-BI has potential as an anticancer therapy, but further studies are needed to understand its full potential and mechanism of action.

CANCERS (2023)

暂无数据